MX2007005547A - Compuestos y composiciones como inhibidores de la proteina cinasa. - Google Patents
Compuestos y composiciones como inhibidores de la proteina cinasa.Info
- Publication number
- MX2007005547A MX2007005547A MX2007005547A MX2007005547A MX2007005547A MX 2007005547 A MX2007005547 A MX 2007005547A MX 2007005547 A MX2007005547 A MX 2007005547A MX 2007005547 A MX2007005547 A MX 2007005547A MX 2007005547 A MX2007005547 A MX 2007005547A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- abl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
La invencion proporciona una clase novedosa de compuestos, composiciones farmaceuticas que comprenden tales compuestos y metodos para utilizar tales compuestos para tratar o prevenir enfermedades o trastornos asociados con la actividad de cinasa anormal y desreglada, particularmente enfermedades o trastornos que implican la activacion anormal de las cinasas Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKCa, Raf, ROCK-II, Rsk1, SGK, TrkA, TrkB, y TRC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62678504P | 2004-11-09 | 2004-11-09 | |
US70964805P | 2005-08-19 | 2005-08-19 | |
PCT/US2005/040372 WO2006052936A2 (en) | 2004-11-09 | 2005-11-07 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007005547A true MX2007005547A (es) | 2007-07-05 |
Family
ID=36337126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005547A MX2007005547A (es) | 2004-11-09 | 2005-11-07 | Compuestos y composiciones como inhibidores de la proteina cinasa. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8101608B2 (es) |
EP (1) | EP1814545A4 (es) |
JP (1) | JP4917041B2 (es) |
KR (1) | KR20070084066A (es) |
AR (1) | AR053652A1 (es) |
AU (1) | AU2005304719B2 (es) |
BR (1) | BRPI0517968A (es) |
CA (1) | CA2583737C (es) |
GT (1) | GT200500321A (es) |
IL (1) | IL182687A0 (es) |
MA (1) | MA29216B1 (es) |
MX (1) | MX2007005547A (es) |
NO (1) | NO20072887L (es) |
RU (1) | RU2406725C2 (es) |
TN (1) | TNSN07176A1 (es) |
TW (1) | TW200631577A (es) |
WO (1) | WO2006052936A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
ATE486859T1 (de) | 2004-10-25 | 2010-11-15 | Ligand Pharm Inc | Verbindungen modulierende thrombopoietinaktivität und verfahren |
WO2007008895A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
CA2602453A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
US8034957B2 (en) | 2006-08-11 | 2011-10-11 | Allergan, Inc. | Kinase inhibitors |
CA2663147A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
CA2664147A1 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
NZ598251A (en) | 2007-03-14 | 2013-06-28 | Exelixis Patent Co Llc | 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer |
CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
EP2252612B1 (en) * | 2008-02-22 | 2012-03-28 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
JP2011520809A (ja) * | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
CN102098918A (zh) * | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | 用于治疗癌症和神经退行性疾病的生物活性化合物 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
CN102115472B (zh) * | 2010-01-04 | 2013-12-04 | 深圳市天和医药科技开发有限公司 | 3-(2-吡咯亚甲基)氮杂吲哚啉-2-酮衍生物及其制法与应用 |
GB201014374D0 (en) * | 2010-08-27 | 2010-10-13 | Univ Greenwich | Novel hybrid compounds |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
RU2642463C2 (ru) | 2012-04-20 | 2018-01-25 | Аннцзи Фармасьютикал Ко., Лтд. | Циклопропанкарбоксилатные эфиры пуриновых аналогов |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
US9296730B2 (en) | 2012-10-26 | 2016-03-29 | Regents Of The University Of Minnesota | Aurora kinase inhibitors |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US10487054B2 (en) | 2017-04-21 | 2019-11-26 | Regents Of The University Of Minnesota | Therapeutic compounds |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
AR120040A1 (es) | 2019-09-27 | 2022-01-26 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
CA3163053A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Amorphous kinase inhibitor formulations and methods of use thereof |
EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
CN114853736B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 具有trk抑制活性的化合物、制备方法、组合物及其用途 |
CN114853735B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 靶向泛素化降解trk的化合物及其制备方法、组合物和用途 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024054793A1 (en) | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
EP1066257A2 (en) * | 1998-03-26 | 2001-01-10 | Sugen, Inc. | Heterocylic classes of compounds for the modulating tyrosine protein kinase |
ATE256659T1 (de) * | 1998-05-28 | 2004-01-15 | Biogen Inc | Ein vla-4-inhibitor: omepupa-v |
CA2314156C (en) | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
AU5468499A (en) * | 1998-08-04 | 2000-02-28 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
AU760039B2 (en) * | 1998-12-17 | 2003-05-08 | F. Hoffmann-La Roche Ag | 4-aryloxindoles as inhibitors of JNK protein kinases |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
NZ520640A (en) * | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
CA2410509A1 (en) * | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
US20030119839A1 (en) * | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
CA2506546A1 (en) | 2002-11-15 | 2004-06-17 | Exelixis, Inc. | Kinase modulators |
-
2005
- 2005-11-04 GT GT200500321A patent/GT200500321A/es unknown
- 2005-11-07 KR KR1020077010439A patent/KR20070084066A/ko active IP Right Grant
- 2005-11-07 EP EP05851419A patent/EP1814545A4/en not_active Withdrawn
- 2005-11-07 MX MX2007005547A patent/MX2007005547A/es active IP Right Grant
- 2005-11-07 BR BRPI0517968-8A patent/BRPI0517968A/pt not_active IP Right Cessation
- 2005-11-07 JP JP2007540153A patent/JP4917041B2/ja not_active Expired - Fee Related
- 2005-11-07 CA CA2583737A patent/CA2583737C/en not_active Expired - Fee Related
- 2005-11-07 AU AU2005304719A patent/AU2005304719B2/en not_active Ceased
- 2005-11-07 AR ARP050104664A patent/AR053652A1/es unknown
- 2005-11-07 RU RU2007121505/04A patent/RU2406725C2/ru not_active IP Right Cessation
- 2005-11-07 US US11/718,886 patent/US8101608B2/en not_active Expired - Fee Related
- 2005-11-07 WO PCT/US2005/040372 patent/WO2006052936A2/en active Application Filing
- 2005-11-08 TW TW094139176A patent/TW200631577A/zh unknown
-
2007
- 2007-04-19 IL IL182687A patent/IL182687A0/en unknown
- 2007-05-08 TN TNP2007000176A patent/TNSN07176A1/fr unknown
- 2007-05-30 MA MA29953A patent/MA29216B1/fr unknown
- 2007-06-06 NO NO20072887A patent/NO20072887L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2583737C (en) | 2011-09-20 |
US20080221192A1 (en) | 2008-09-11 |
IL182687A0 (en) | 2007-09-20 |
GT200500321A (es) | 2006-09-04 |
TW200631577A (en) | 2006-09-16 |
US8101608B2 (en) | 2012-01-24 |
AU2005304719B2 (en) | 2009-07-23 |
EP1814545A4 (en) | 2009-06-10 |
BRPI0517968A (pt) | 2008-10-21 |
RU2406725C2 (ru) | 2010-12-20 |
CA2583737A1 (en) | 2006-05-18 |
WO2006052936A3 (en) | 2006-10-26 |
TNSN07176A1 (en) | 2008-11-21 |
AU2005304719A1 (en) | 2006-05-18 |
WO2006052936A2 (en) | 2006-05-18 |
MA29216B1 (fr) | 2008-02-01 |
JP2008519762A (ja) | 2008-06-12 |
EP1814545A2 (en) | 2007-08-08 |
AR053652A1 (es) | 2007-05-16 |
RU2007121505A (ru) | 2008-12-20 |
KR20070084066A (ko) | 2007-08-24 |
NO20072887L (no) | 2007-08-03 |
JP4917041B2 (ja) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
WO2006124462A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2006101783A3 (en) | Compounds and compositions as protein kinase inhibitors | |
PT1940844E (pt) | Compostos e composições como inibidores de proteína-quinase | |
TNSN06406A1 (en) | Compounds and compositions as protein kinase inhibitors | |
DE602006014540D1 (en) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
EA201000325A1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
NI200900061A (es) | Composiciones y métodos para la modulación de los receptores c-kit y pdgf. | |
NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
ATE499374T1 (de) | Verbindungen und zusammensetzungen als proteinkinase-hemmer | |
MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
WO2005039486A3 (en) | Compounds and compositions as protein kinase inhibitors | |
TH79792B (th) | สารประกอบและสารผสมที่เป็นสารยับยั้งโปรตีนไคเนส | |
TH79792A (th) | สารประกอบและสารผสมที่เป็นสารยับยั้งโปรตีนไคเนส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |